Wave Life Sciences .(US:WVE) Globenewswireยท2025-07-30 11:30Core Insights - Wave Life Sciences is advancing its clinical programs, particularly WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD) and WVE-007 for obesity, with significant milestones expected in the coming years [1][2][3] AATD Program (WVE-006) - WVE-006 is designed to correct AAT protein and address lung and liver manifestations of AATD, with multi-dosing complete in the first cohort (200 mg) and single dosing complete in the second cohort (400 mg) [1][3] - Data from the complete 200 mg cohorts are expected in Q3 2025, while data from the 400 mg cohort are anticipated in fall 2025 [1][7] - Positive proof-of-mechanism data from a single dose of WVE-006 showed a mean total AAT protein level that met regulatory approval standards for AAT augmentation therapies [2][4] Obesity Program (WVE-007) - WVE-007 is an INHBE GalNAc-siRNA aimed at inducing fat loss while preserving muscle, with dosing complete in an expanded cohort of the INLIGHT trial [1][3] - The expansion of Cohort 2 was based on favorable safety and tolerability data, with results from both Cohort 1 and Cohort 2 expected in Q4 2025 [3][7] - Preclinical data indicated that a single dose of WVE-007 led to significant reductions in INHBE mRNA and Activin E protein, driving weight loss comparable to semaglutide [3][7] Financial Overview - As of June 30, 2025, the company reported cash and cash equivalents of $208.5 million, sufficient to fund operations into 2027 [1][9] - Revenue for Q2 2025 was $8.7 million, a decrease from $19.7 million in the same quarter of the previous year [9][20] - The net loss for Q2 2025 was $50.5 million, compared to a net loss of $32.9 million in Q2 2024 [9][20] Corporate Developments - In May 2025, the company appointed Christopher Wright, MD, PhD, as Chief Medical Officer, enhancing its leadership in global development [10] - Wave Life Sciences plans to host a Research Day in fall 2025 to share updates on its clinical and preclinical pipeline [3][7]